Galapagos N.V. (GLPG) News & Overview - Discounting Cash Flows
GLPG
Galapagos N.V.
GLPG (NASDAQ)

General Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Sector & Industry Healthcare / Biotechnology
Website https://www.glpg.com
IPO date February 27, 2012

GLPG Latest News

Other Identifiers
CIK0001421876
ISINUS36315X1019
CUSIP36315X101
Open27.97
Previous Close27.87
Volume118.1 Thou.
Average Volume389.3 Thou.
Day’s Range27.96 – 28.695
52 Week Range22.36-31.23
MA (50)27.617
MA (200)26.87495
Market Cap1.88 Bil.
Shares Out.65.9 Mil.
Earnings DateJul 23, 2025
Beta
Last Dividend
EPS
PE
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us